Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | |||||||||||||
Title | Azedra (iobenguane I 131) FDA Drug Label | ||||||||||||
|
|||||||||||||
URL | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209607 | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
131I-MIBG | Azedra | I131 Metaiodobenzylguanidine iodine|iobenguane I 131 | Azedra (iobenguane I 131) is a norepinephrine-like molecule labeled with radioactive I 131, which can be used to image or eliminate tumor cells overexpressing norepinephrine transporters (PMID: 25874239). Azedra (iobenguane I 131) is FDA approved for use in adult and pediatric patients 12 years and older with iobenguane scan positive pheochromocytoma or paraganglioma (FDA.gov). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|